5
|
Barakat L, Torres MJ, Phillips EJ, Caminati M, Chang YS, Caimmi D, Sanchez-Borges M, Rosenwasser L, Didier A, de Blay F, Fontaine JF, Bosse I, Lefevre S, Bassani C, De Filippo M, Asontegui I, Morais-Almeida M, Ebisawa M, Martin B, Thong BYH, Demoly P, Tanno LK. Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions. J Allergy Clin Immunol Pract 2020; 9:1396-1399.e2. [PMID: 33161172 DOI: 10.1016/j.jaip.2020.10.044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 10/18/2020] [Accepted: 10/22/2020] [Indexed: 12/20/2022]
Affiliation(s)
- Leyla Barakat
- Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier, Montpellier, France
| | - Maria Jose Torres
- Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-ARADyAL-BIONAND, Malaga, Spain
| | - Elizabeth J Phillips
- Center for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Centre, Nashville, Tenn; Vanderbilt University School of Medicine, Vanderbilt University, Nashville, Tenn; Centre for Clinical Pharmacology and Infectious Diseases, Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia
| | - Marco Caminati
- Department of Medicine, Allergy Asthma and Clinical Immunology Section, University of Verona, Verona, Italy
| | - Yoon-Seok Chang
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - Davide Caimmi
- Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier, Montpellier, France; Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France
| | - Mario Sanchez-Borges
- Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad and Clínica el Avila, Caracas, Venezuela
| | - Lanny Rosenwasser
- Department of Pediatrics, Division of Immunology Research, Children's Mercy Hospitals & Clinics, Kansas City, Mo
| | - Alain Didier
- Pôle des Voies Respiratoires, Hôpital Larrey, CHU de Toulouse, Toulouse, France; Centre de Physiopathologie Toulouse Purpan, INSERM U1043, CNRS UMR 5282, Université Toulouse III, Toulouse, France
| | - Frédéric de Blay
- Chest Diseases Department, University Hospital of Strasbourg, Strasbourg, France
| | - Jean-François Fontaine
- Département des maladies allergiques et respiratoires, University Hospital of Reims, Reims, France
| | | | - Sebastien Lefevre
- Regional Institute for Allergic and Environmental Diseases, Metz Regional Hospital, Metz, France
| | - Cintia Bassani
- Department of Allergy and Clinical Immunology, IMED School of Medicine, Passo Fundo, Brazil
| | - Maria De Filippo
- Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, and Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
| | - Igancio Asontegui
- Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia Erandio, Bilbao, Spain
| | | | - Motohiro Ebisawa
- Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan
| | - Bryan Martin
- Medicine and Pediatrics, The Ohio State University, Columbus, Ohio
| | - Bernard Yu-Hor Thong
- Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore
| | - Pascal Demoly
- Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier, Montpellier, France; Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France; WHO Collaborating Centre on Scientific Classification Support, Montpellier, France
| | - Luciana Kase Tanno
- Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier, Montpellier, France; Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France; WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.
| |
Collapse
|
7
|
Lefevre S, Lusque A, Joyon N, Arnould L, Penault-Llorca F, MacGrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzalez A, Charafe-Jauffret E, Courtinard C, Franchet C, Verriele V, Brain E, Tas P, Delaloge S, Filleron T, LaCroix-Triki M. Abstract P5-12-05: Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Therapeutic options at diagnosis for metastatic breast cancers (MBC) differ largely according to cancer phenotype (namely, hormone receptor (HR) and HER2 status). Reported discordance rates between primary tumor and metastasis vary widely in literature, with a median of 18% for estrogen receptor, 31% for progesterone receptor and 10% for HER2. The present study aimed to compare phenotypic profiles between primary and MBC in the real-life setting.
Patients (pts) and methods:
Epidemio-Strategy and Medical Economics (ESME)MBC data platform (NCT03275311) is a French national, multicenter, observational cohort using clinical trials' methodology for data capture, monitoring and quality controls. At the time of analysis, it comprised data of 16703 consecutive newly diagnosed MBC pts (1/01/08-31/12/14) treated in 18 French comprehensive cancer centres. The primary endpoint was the discordance rate of HR and HER2 status between primary tumor and MBC (biopsy of metastatic site done within 6 months of MBC diagnosis). Only patients with both histological reports available were considered. Potential factors associated with phenotype discordance were assessed in a multivariate logistic regression.
Results: 2933 out of 16703 (17.6%) had a biopsy in the first 6 months of metastatic disease. HR and/or HER2 status was available in 1677 pts. The discordance rate between primary and matched MBC was 14.2% (222/1566) for HR: loss of expression in 72.5%, gain in 27.5%. For HER2, the discordance rate was 7.8% (84/1076): 45.2% of losses and 54.8% of gains of expression. The primary HR+/HER2+ subgroup had the highest rate of changes: 53% (49/92) with either a loss of HR (43%), loss of HER2 (43%) or a loss of both (14%). 18% (33/181) of primary triple-negative breast cancer (TNBC) had a phenotypic change with a majority of HR gain (79%). In multivariate analysis, administration of adjuvant chemotherapy +/- targeted therapy was the sole independent predictor of HR status modification (OR: 1.73, 95%CI 1.27-2.36, p=0.001). The presence of a mixed histology was the only predictor of HER2 discordance (OR =2.57, 95%CI 1.19-5.55, p=0.016).
Patient characteristics Total population (n=16703)Pts with primary and MBC phenotype available (n=1677)Age at metastatic diagnosis Median (range)61 (19-99)60 (24-93)De novo MBC4507 (27.1%)221 (13.2%)Number of metastatic sites Median (range)1 (1-9)2 (1-7)MBC sites Brain1200 (7.2%)138 (8.2%)Visceral7755 (46.4%)928 (55.3%)Non-visceral7748 (46.4%)611 (36.4%)Phenotypic profileN = 2933N=1677TNBC356 (18.5%)272 (19.3%)HR+/HER2-1251 (65.0%)917 (65.2%)HR-/HER2+150 (7.8%)105 (7.5%)HR+/HER2+168 (8.7%)112 (8%)Missing1008271Metastatic site samplingN=2933N=1677Bone692 (24.2%)419 (25.5%)Liver514 (18.0%)355 (21.6%)Skin379 (13.3%)203 (12.4%)Node306 (10.7%)169 (10.3%)Lung258 (9.0%)168 (10.2%)Pleura283 (9.9%)121 (7.4%)CNS/CSF*132 (4.6%)42 (2.6%)Other or multiple296 (10.3%)165 (10.0%)Missing7335* CNS= central nervous system, CSF=cerebro-spinal fluid
Conclusion: Biopsy and phenotype re-evaluation of MBC early in the disease course has a confirmed potential significant therapeutic impact in this large scale real life setting and should be proposed as often as possible.
Citation Format: Lefevre S, Lusque A, Joyon N, Arnould L, Penault-Llorca F, MacGrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzalez A, Charafe-Jauffret E, Courtinard C, Franchet C, Verriele V, Brain E, Tas P, Delaloge S, Filleron T, LaCroix-Triki M. Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-05.
Collapse
Affiliation(s)
- S Lefevre
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - A Lusque
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - N Joyon
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - L Arnould
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - F Penault-Llorca
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - G MacGrogan
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - I Treilleux
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - A Vincent-Salomon
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - J Haudebourg
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - A Maran-Gonzalez
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - E Charafe-Jauffret
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - C Courtinard
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - C Franchet
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - V Verriele
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - E Brain
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - P Tas
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - S Delaloge
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - T Filleron
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - M LaCroix-Triki
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| |
Collapse
|